NMRA 8-K: SEC filing
Neumora Therapeutics
Filed with the SEC on · accession 0001193125-26-462165
NMRA filed a 8-K (current report) with the SEC on Nov 16, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Neumora Therapeutics announced its financial results for the third quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to its Form 8-K.
Key details
✦ Ask GOAX AI about this filing — what it means for NMRA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NMRA?
Click hereFrequently asked questions
What did NMRA file with the SEC on Nov 16, 2026?
NMRA filed a 8-K (SEC filing). Neumora Therapeutics announced its financial results for the third quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to its Form 8-K.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other NMRA SEC filings
Get alerts when NMRA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days